Your browser doesn't support javascript.
loading
Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
van Heek, Lutz; Weindler, Jasmin; Gorniak, Claudia; Kaul, Helen; Müller, Horst; Mettler, Jasmin; Baues, Christian; Fuchs, Michael; Borchmann, Peter; Ferdinandus, Justin; Dietlein, Markus; Voltin, Conrad-Amadeus; Kobe, Carsten; Roth, Katrin S.
Afiliación
  • van Heek L; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Weindler J; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Gorniak C; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kaul H; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Müller H; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Mettler J; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Baues C; Department of Radiooncology, Marienhospital Herne, Ruhr University Bochum, Bochum, Germany.
  • Fuchs M; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Borchmann P; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Ferdinandus J; First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen-Bonn-Cologne-Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Dietlein M; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Voltin CA; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Kobe C; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Roth KS; Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Eur J Haematol ; 111(6): 881-887, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37644732
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Haematol Asunto de la revista: HEMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania